1877 Stock Overview
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People’s Republic of China.
Shanghai Junshi Biosciences Co., Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$31.70|
|52 Week High||HK$68.65|
|52 Week Low||HK$29.90|
|1 Month Change||-17.56%|
|3 Month Change||-42.52%|
|1 Year Change||-32.41%|
|3 Year Change||4.45%|
|5 Year Change||n/a|
|Change since IPO||33.47%|
Recent News & Updates
|1877||HK Biotechs||HK Market|
Return vs Industry: 1877 exceeded the Hong Kong Biotechs industry which returned -51.8% over the past year.
Return vs Market: 1877 underperformed the Hong Kong Market which returned -21.6% over the past year.
|1877 Average Weekly Movement||9.5%|
|Biotechs Industry Average Movement||7.8%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||12.6%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 1877 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 1877's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People’s Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection.
Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary
|1877 fundamental statistics|
Is 1877 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1877 income statement (TTM)|
|Cost of Revenue||CN¥1.14b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.64|
|Net Profit Margin||-49.18%|
How did 1877 perform over the long term?See historical performance and comparison